Medical Supervision Required: Peptide Tracker is for private logging, calculations, reminders, inventory records, and education. It is not medical advice, dosing instruction, prescribing guidance, diagnosis, or a substitute for a qualified healthcare professional.
Brand Names

What Is Victoza?

Published May 2, 2026 · 4 minute read

Victoza is one of the GLP-1 brand names that predates the current wave of semaglutide, tirzepatide, and weight-loss headlines. It illustrates how one product can be a brand name, a liraglutide injection, a GLP-1 receptor agonist, a type 2 diabetes treatment, and a generic reference point.

Key Takeaways

  • Victoza is Novo Nordisk's brand name for liraglutide injection.
  • Current U.S. labeling describes Victoza as a GLP-1 receptor agonist for type 2 diabetes.
  • The Victoza label includes cardiovascular-risk reduction language for adults with type 2 diabetes and established cardiovascular disease.
  • The FDA announced the first generic referencing Victoza on December 23, 2024.
  • Victoza and Saxenda both contain liraglutide, but are approved for different uses.

1. What Is Victoza?

Victoza is Novo Nordisk’s brand name for liraglutide injection. The current DailyMed Victoza label describes Victoza as a glucagon-like peptide-1, or GLP-1, receptor agonist indicated for type 2 diabetes glycemic control in adults and pediatric patients aged 10 years and older.

In this definition, “Victoza” is the brand, “liraglutide” is the active ingredient, and “GLP-1 receptor agonist” is the medication class.

The label also includes defined cardiovascular-risk context: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. This applies to a specific labeled population rather than being a general “heart benefit.”

For broader class background, see What Is a GLP-1?.

2. Why Victoza Still Matters

Victoza is a recognizable early GLP-1 brand, a liraglutide reference point, and now part of the generic GLP-1 market. The FDA’s December 23, 2024 announcement described the approval of the first generic referencing Victoza.

This shows that liraglutide has been on the U.S. market long enough to transition into a generic-reference conversation. It serves as a reminder that not every GLP-1 brand belongs to the same era. While some newer names are associated with weekly injections, oral tablets, or weight loss, Victoza is a daily liraglutide injection with a long-established history for type 2 diabetes.

Victoza contains the active ingredient liraglutide. DailyMed identifies Victoza as a liraglutide injection, while the FDA’s Victoza information page frames liraglutide as marketed as Victoza for type 2 diabetes.

Here is the distinction:

LayerVictoza exampleWhat it tells you
Brand nameVictozaThe marketed product name.
Active ingredientLiraglutideThe molecule in the product.
Class wordingGLP-1 receptor agonistThe receptor category used in labeling.
Label contextType 2 diabetesThe approved medical use tied to the brand label.
Generic referenceLiraglutide injection referencing VictozaThe regulatory baseline for generic approvals.

Liraglutide is the active ingredient in multiple products, including Victoza, Saxenda, and new generic product records.

4. Victoza vs Saxenda

Victoza and Saxenda both contain liraglutide, but they are approved for different uses. The current DailyMed Victoza label is for type 2 diabetes, while the DailyMed Saxenda label is for chronic weight management.

NameActive ingredientHigh-level U.S. brand context
VictozaLiraglutideType 2 diabetes label, with defined cardiovascular-risk reduction wording for some adults with type 2 diabetes and established cardiovascular disease.
SaxendaLiraglutideChronic weight-management label.

5. Victoza vs Ozempic, Trulicity, Mounjaro, and Zepbound

Victoza differs from Ozempic, Rybelsus, Wegovy, Trulicity, Mounjaro, and Zepbound because those names point to different active ingredients entirely.

Here is a comparison of these brand families:

Brand familyActive ingredientMedication Class
Victoza, SaxendaLiraglutideGLP-1 receptor agonist
Ozempic, Rybelsus, WegovySemaglutideGLP-1 receptor agonist
TrulicityDulaglutideGLP-1 receptor agonist
Mounjaro, ZepboundTirzepatideGIP receptor and GLP-1 receptor agonist

6. Generic Liraglutide and Victoza

The FDA announced on December 23, 2024, that it approved the first generic referencing Victoza, liraglutide injection, for type 2 diabetes. The FDA described the product as a once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes.

This regulatory milestone means that there is now a generic pathway for liraglutide injections based on Victoza’s original clinical data and approval record.

7. What Is Victoza FAQ

  • What is Victoza in simple terms?

    Victoza is Novo Nordisk's brand name for liraglutide injection. It is a GLP-1 receptor agonist used for type 2 diabetes glycemic control, and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease.

  • Is Victoza the same thing as liraglutide?

    Liraglutide is the active ingredient. Victoza is a specific brand name for a liraglutide injection product. Saxenda and generic products also contain liraglutide.

  • How is Victoza different from Saxenda?

    Victoza and Saxenda both contain liraglutide, but they are approved for different uses. Victoza is prescribed for type 2 diabetes, while Saxenda is prescribed for chronic weight management.

  • Is there a generic version of Victoza?

    Yes. The FDA announced on December 23, 2024, that it approved the first generic referencing Victoza (liraglutide injection) for type 2 diabetes.

8. Sources

References used for this article

Download for iOS